Second-line Treatment of Metastatic Colorectal Cancer

The goal of this multicenter, single-arm, observational cohort study is to investigate the efficacy and safety of irinotecan in combination with trifluridine-tipiracil and bevacizumab in colorectal cancer with prior oxaliplatin and fluoropyrimidine-based chemotherapy (including 5-FU/capecitabine/S-1) exposure in the metastatic setting or within 12 months of recurrence.

Trial Details

NCT ID

NCT06242067

Phase

PHASE2

Sponsor

Qilu Hospital of Shandong University

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

Trifluridine/tipiracil

Locations (sample)

Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

All subjects are required to sign an informed consent form before starting the study-related procedure
Age 18-75 years old, male or female.
have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1, life expectancy \>3 months.
Histologically or cytological proven metastatic or recurrent adenocarcinoma of the colon or rectum.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →